BR112016023980A2 - anticorpos monoclonais recombinantes vnar que neutralizam o fator de crescimento endotelial vascular (vegf) - Google Patents
anticorpos monoclonais recombinantes vnar que neutralizam o fator de crescimento endotelial vascular (vegf)Info
- Publication number
- BR112016023980A2 BR112016023980A2 BR112016023980A BR112016023980A BR112016023980A2 BR 112016023980 A2 BR112016023980 A2 BR 112016023980A2 BR 112016023980 A BR112016023980 A BR 112016023980A BR 112016023980 A BR112016023980 A BR 112016023980A BR 112016023980 A2 BR112016023980 A2 BR 112016023980A2
- Authority
- BR
- Brazil
- Prior art keywords
- vnar
- vegf
- growth factor
- vascular endothelial
- endothelial growth
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
a presente invenção refere-se à seleção, isolamento e purificação de proteínas que pertencem a regiões variáveis chamadas de vhnar ou vnar, originadas a partir de imunoglobulinas do tipo ignar de elasmobrânquios com capacidade de receptor de antígeno. os clones a partir dos quais as mesmas se originam são chamados de vegfvnar v32r e v19; e os anticorpos são chamados de v32r e v19. suas sequências de aminoácidos e estruturas terciárias foram elucidadas, e sua capacidade para neutralizar a atividade de fator de crescimento endotelial vascular (vegf) foi determinada. durante o desenvolvimento da invenção, essas proteínas foram otimizadas para a expressão em um modelo de produção de e.coli em nível industrial. a invenção envolve o uso desses anticorpos em geral para tratar afecções relacionadas à angiogênese ou neovascularização e, em particular, para tratar afecções oftálmicas relacionadas à neovascularização por meio de administração tópica.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/ES2014/070332 WO2015158937A1 (es) | 2014-04-17 | 2014-04-17 | ANTICUERPOS MONOCLONALES RECOMBINANTES vNAR NEUTRALIZANTES DEL FACTOR DE CRECIMIENTO DEL ENDOTELIO VASCULAR VEGF |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112016023980A2 true BR112016023980A2 (pt) | 2017-10-17 |
Family
ID=50877332
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016023980A BR112016023980A2 (pt) | 2014-04-17 | 2014-04-17 | anticorpos monoclonais recombinantes vnar que neutralizam o fator de crescimento endotelial vascular (vegf) |
Country Status (16)
Country | Link |
---|---|
US (1) | US10370442B2 (pt) |
EP (1) | EP3133085A1 (pt) |
JP (1) | JP6426198B2 (pt) |
KR (1) | KR20160145166A (pt) |
CN (1) | CN106459193A (pt) |
AR (1) | AR101647A1 (pt) |
AU (1) | AU2014391247A1 (pt) |
BR (1) | BR112016023980A2 (pt) |
CA (1) | CA2946086A1 (pt) |
IL (1) | IL248320A0 (pt) |
MX (1) | MX2016013613A (pt) |
RU (1) | RU2016145136A (pt) |
SG (1) | SG11201608659TA (pt) |
TW (1) | TWI547501B (pt) |
UY (1) | UY36082A (pt) |
WO (1) | WO2015158937A1 (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102341446B1 (ko) * | 2016-09-29 | 2021-12-21 | 네이처와이즈 바이오테크 & 메디칼스 코포레이션 | 안구 질병을 치료하는 방법 |
WO2018194441A1 (es) * | 2017-04-21 | 2018-10-25 | Centro De Investigación Científica Y De Educación Superior De Ensenada, Baja California | Vnar con actividad anti-angiogénica en tumores sólidos de animales de compañía |
CN109593117B (zh) * | 2019-01-11 | 2021-12-31 | 广州领晟医疗科技有限公司 | 一种用于抑制血管新生的多肽cka18n及其应用 |
CN109776656B (zh) * | 2019-01-11 | 2022-03-11 | 广州领晟医疗科技有限公司 | 一种用于抑制血管新生的多肽tin7n及其应用 |
EP4141028A1 (en) | 2021-08-31 | 2023-03-01 | Johann-Wolfgang-Goethe-Universität Frankfurt am Main | Personalized vnar-based chimeric antigen receptors (vnar-car) for the treatment of clonal b-and t cell malignancies, and methods for producing vnar-cars |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7977071B2 (en) * | 2004-06-02 | 2011-07-12 | Adalta Pty Ltd. | Binding moieties based on shark ignar domains |
WO2010033913A1 (en) * | 2008-09-22 | 2010-03-25 | Icb International, Inc. | Antibodies, analogs and uses thereof |
US20100136584A1 (en) * | 2008-09-22 | 2010-06-03 | Icb International, Inc. | Methods for using antibodies and analogs thereof |
EP2344545A4 (en) * | 2008-10-06 | 2012-10-03 | Commw Scient Ind Res Org | CRYSTALLINE STRUCTURE OF BETA-AMYLOID PEPTIDE |
JP2012527876A (ja) * | 2009-05-28 | 2012-11-12 | グラクソ グループ リミテッド | 抗原結合タンパク質 |
US8496933B2 (en) | 2009-11-04 | 2013-07-30 | Laboratorios Silanes, S.A. De C.V. | VHNAR anti-cytokine domains |
-
2014
- 2014-04-17 RU RU2016145136A patent/RU2016145136A/ru not_active Application Discontinuation
- 2014-04-17 EP EP14727573.9A patent/EP3133085A1/en not_active Withdrawn
- 2014-04-17 CA CA2946086A patent/CA2946086A1/en not_active Abandoned
- 2014-04-17 US US15/304,516 patent/US10370442B2/en active Active
- 2014-04-17 BR BR112016023980A patent/BR112016023980A2/pt not_active IP Right Cessation
- 2014-04-17 KR KR1020167032052A patent/KR20160145166A/ko not_active Application Discontinuation
- 2014-04-17 CN CN201480078046.3A patent/CN106459193A/zh active Pending
- 2014-04-17 SG SG11201608659TA patent/SG11201608659TA/en unknown
- 2014-04-17 JP JP2016562017A patent/JP6426198B2/ja not_active Expired - Fee Related
- 2014-04-17 MX MX2016013613A patent/MX2016013613A/es unknown
- 2014-04-17 WO PCT/ES2014/070332 patent/WO2015158937A1/es active Application Filing
- 2014-04-17 AU AU2014391247A patent/AU2014391247A1/en not_active Abandoned
-
2015
- 2015-04-07 AR ARP150101038A patent/AR101647A1/es unknown
- 2015-04-10 TW TW104111642A patent/TWI547501B/zh not_active IP Right Cessation
- 2015-04-15 UY UY0001036082A patent/UY36082A/es not_active Application Discontinuation
-
2016
- 2016-10-13 IL IL248320A patent/IL248320A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
AR101647A1 (es) | 2017-01-04 |
WO2015158937A1 (es) | 2015-10-22 |
EP3133085A1 (en) | 2017-02-22 |
US10370442B2 (en) | 2019-08-06 |
CA2946086A1 (en) | 2015-10-22 |
JP2017513475A (ja) | 2017-06-01 |
US20170137504A1 (en) | 2017-05-18 |
UY36082A (es) | 2015-11-30 |
RU2016145136A3 (pt) | 2018-08-08 |
CN106459193A (zh) | 2017-02-22 |
KR20160145166A (ko) | 2016-12-19 |
AU2014391247A1 (en) | 2016-12-08 |
TWI547501B (zh) | 2016-09-01 |
MX2016013613A (es) | 2017-02-28 |
SG11201608659TA (en) | 2016-12-29 |
JP6426198B2 (ja) | 2018-11-21 |
IL248320A0 (en) | 2016-11-30 |
RU2016145136A (ru) | 2018-05-17 |
TW201546090A (zh) | 2015-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20181336A1 (es) | Anticuerpos que se unen a interleucina 8 (il-8) y sus usos | |
PE20181363A1 (es) | Variantes optimizadas de anticuerpos anti-vegf | |
MX2017014908A (es) | Proteinas de union triespecificas y metodos de uso. | |
BR112017027778A2 (pt) | anticorpos para o fator xi e métodos de uso | |
BR112017009817A2 (pt) | anticorpos anti-il-1beta e métodos de utilização | |
BR112016023980A2 (pt) | anticorpos monoclonais recombinantes vnar que neutralizam o fator de crescimento endotelial vascular (vegf) | |
PE20181270A1 (es) | Anticuerpo que neutraliza el virus respiratorio sincitial humano | |
EA201990019A1 (ru) | Соединения и композиции для подавления активности shp2 | |
WO2017193032A3 (en) | Bispecific binding proteins and uses thereof | |
HRP20161740T1 (hr) | Ljudske molekule za vezanje koje su sposobne neutralizirati viruse influence a filogenetske skupine 1 i filogenetske skupine 2, te viruse influence b | |
BR112017009790A2 (pt) | anticorpos direcionados ao anti-ang2 e métodos de uso | |
EA201790342A1 (ru) | Антитела к trem2 и способы их применения | |
JP2014237714A5 (pt) | ||
AR110321A1 (es) | Anticuerpos antitau y métodos de uso | |
BR112018006579A2 (pt) | anticorpos anti-humanos cd19 humanizados e métodos de uso | |
RU2018132044A (ru) | Антитела против тау | |
BR112016013347A8 (pt) | anticorpo monoclonal humano neutralizante anti-il-33,composição farmacêutica,inibidor da expressão de citocinas,epitopo,molécula de ácido nucleico,vetor,célula hospedeira,método de produção e uso dos mesmos. | |
JP2014221758A5 (pt) | ||
JP2017518258A5 (pt) | ||
UA117097C2 (uk) | Антитіло проти лігандів рецептора в1 брадикініну | |
MD3261720T2 (ro) | Anticorpi anti-Tau și utilizările acestora | |
UA113623C2 (uk) | Моноклональне антитіло проти інгібітору шляху тканинного фактора (tfpi) | |
UA118354C2 (uk) | Антитіло до рецептора колонієстимулювального фактора (кфс-1r) | |
BR112022009317A2 (pt) | Anticorpos de cd73 biparatópicos | |
WO2015127140A3 (en) | Marburg monoclonal antibodies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2562 DE 2020-02-11 |
|
B350 | Update of information on the portal [chapter 15.35 patent gazette] |